Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $20.00 by Analysts at Piper Sandler

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price target reduced by Piper Sandler from $21.00 to $20.00 in a report issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Piper Sandler’s target price would suggest a potential downside of 6.06% from the company’s current price.

Several other analysts also recently commented on the company. Wells Fargo & Company increased their target price on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a research note on Friday. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Zacks Research raised Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Barclays dropped their price objective on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Wednesday, June 3rd. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, July 8th. Six equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $22.00.

Amphastar Pharmaceuticals Stock Up 7.5%

Amphastar Pharmaceuticals stock traded up $1.48 during trading hours on Friday, hitting $21.29. The stock had a trading volume of 494,338 shares, compared to its average volume of 527,064. The stock’s 50-day moving average price is $19.63 and its 200-day moving average price is $21.40. The stock has a market capitalization of $938.68 million, a P/E ratio of 12.81, a price-to-earnings-growth ratio of 4.27 and a beta of 0.89. Amphastar Pharmaceuticals has a 12-month low of $16.65 and a 12-month high of $31.26. The company has a quick ratio of 2.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. The firm had revenue of $183.90 million for the quarter, compared to analysts’ expectations of $179.92 million. Equities research analysts anticipate that Amphastar Pharmaceuticals will post 2.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp bought a new stake in shares of Amphastar Pharmaceuticals in the second quarter worth $4,689,000. State of Wyoming bought a new position in Amphastar Pharmaceuticals in the second quarter valued at about $142,000. Pacer Advisors Inc. boosted its position in Amphastar Pharmaceuticals by 47.1% in the first quarter. Pacer Advisors Inc. now owns 261,483 shares of the company’s stock worth $5,122,000 after purchasing an additional 83,739 shares during the last quarter. Segall Bryant & Hamill LLC boosted its position in Amphastar Pharmaceuticals by 197.9% in the first quarter. Segall Bryant & Hamill LLC now owns 33,318 shares of the company’s stock worth $653,000 after purchasing an additional 22,133 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Amphastar Pharmaceuticals by 36.0% during the 1st quarter. Bank of America Corp DE now owns 174,323 shares of the company’s stock valued at $3,415,000 after purchasing an additional 46,149 shares during the period. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals News Summary

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Adjusted earnings and revenue beat estimates: Amphastar reported adjusted EPS of $0.91, well above the $0.62–$0.66 analyst consensus range and up from $0.85 a year earlier. Revenue reached $183.9 million, exceeding the approximately $179.9 million consensus estimate. Amphastar Pharmaceuticals Reports Financial Results
• Positive Sentiment: Solid profitability: GAAP net income was $30.3 million, or $0.67 per share, while adjusted non-GAAP net income totaled $40.8 million, or $0.91 per share. The earnings beat strengthens the investment case by demonstrating better-than-expected operating performance in the quarter. Amphastar Q2 Earnings and Revenues Top Estimates
• Neutral Sentiment: Investor focus shifts to the outlook: The Q2 earnings call and related analysis provide additional commentary on key business metrics and management’s expectations, but the available reports do not identify a major new guidance change. Amphastar Q2 2026 Earnings Call Transcript
• Negative Sentiment: Wells Fargo remains cautious: The firm raised its price target from $19 to $20 but maintained an “equal weight” rating. The new target remains below the stock’s recent trading level, signaling that Wells Fargo views the shares as fairly valued to modestly overvalued despite the earnings beat. Benzinga analyst report

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.